Skip to main content

Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?

Clinical Pharmacokinetics volume 58, pages 977–978 (2019)Cite this article

A Letter to the Editor to this article was published on 12 June 2019

The Original Article was published on 04 April 2019

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-007747-3.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lindenblatt, et al. Solid pharmaceutical preparation containing levothyroxine. United States Patent Application Publication. Merck patent GMBH. US 2015/0231101 A1. 2015.

  3. ANSM. Direction des contrôles. 12/09/2017. Note de synthèse 17-A-033.

  4. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministrated with various calcium formulations. Thyroid. 2011;21:483–6.

    Article  CAS  Google Scholar 

  5. Poole RA, Kasper PT, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22.

    Article  CAS  Google Scholar 

  6. Chumsae C, Zhou LL, Shen Y, Wohlgemuth J, Fung E, Burton R, et al. Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody. Anal Chem. 2014;86:8932–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Honorary Hospital Practitioner, Pharmacology and Toxicology, CHRU, 110 Avenue de Boufflers, 54000, Nancy, France

    Philippe Tréchot

Authors
  1. Philippe Tréchot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Tréchot.

Ethics declarations

Funding

No external funds were used in the preparation of this letter.

Conflict of interest

Philippe Tréchot declares no potential conflicts of interest that might be relevant to the contents of this letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tréchot, P. Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?. Clin Pharmacokinet 58, 977–978 (2019). https://doi.org/10.1007/s40262-019-00784-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-019-00784-y